18 results
10-K
2020 FY
KRBP
Kiromic Biopharma, Inc.
31 Mar 21
Annual report
11:41am
materials, which could adversely impact the timing of the commercial launch of the product.
Regenerative Medicine Advanced Therapy, or RMAT, designation … , if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.
Regenerative
DRS
KRBP
Kiromic Biopharma, Inc.
15 Nov 19
Draft registration statement
12:00am
such designations.
Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster … may seek Regenerative Medicine Advanced Therapy, or RMAT, designation for one or more of our product candidates. In 2017, the FDA established the RMAT
DRS/A
KRBP
Kiromic Biopharma, Inc.
8 Apr 20
Draft registration statement (amended)
12:00am
such designations.
Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development … Regenerative Medicine Advanced Therapy, or RMAT, designation for one or more of our product candidates. In 2017, the FDA established the RMAT
S-1
KRBP
Kiromic Biopharma, Inc.
11 May 20
IPO registration
1:26pm
may seek orphan drug designation for other product candidates, we may never receive such designations.
Index to Financial Statements
Regenerative … or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
We may seek Regenerative
424B4
yvx26zz1
30 Jun 21
Prospectus supplement with pricing info
5:00pm
DRS
t2t2jp6y1vm z8jwrvd
11 Jun 21
Draft registration statement
12:00am
424B4
97ajkqy5
16 Oct 20
Prospectus supplement with pricing info
3:47pm
- Prev
- 1
- Next